Corsair Pharma to Present Three Phase 1 Clinical Data Readouts for TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association Conference
Corsair Pharma, Inc., a privately held biopharmaceutical company focused on innovative drug delivery systems for cardiopulmonary diseases, has announced three scientific presentations related to its lead clinical program at the upcoming Pulmonary Hypertension Association (PHA) meeting, scheduled for June 11–14, 2026, in Dallas, Texas. The presentations will highlight new clinical findings from the company’s TRX-248 Transdermal System, an investigational once-daily patch designed for the treatment of pulmonary arterial hypertension (PAH).
The announcements come at a time when prostacyclin-based therapies remain a cornerstone of PAH management, particularly in patients with more advanced disease. Despite their clinical effectiveness, current prostacyclin delivery methods—including continuous intravenous infusion, subcutaneous administration, inhaled formulations, and oral therapies—are often associated with treatment burden, fluctuating drug levels, and tolerability challenges. Corsair Pharma is seeking to address these limitations through a novel transdermal drug delivery approach that aims to provide steady systemic exposure with improved convenience and potentially better tolerability.
Advancing a Novel Transdermal Prostacyclin Approach
At the center of Corsair’s development program is the TRX-248 Transdermal System, an investigational once-daily patch engineered to deliver treprostinil, a well-established prostacyclin analog used in the treatment of pulmonary arterial hypertension. Unlike conventional formulations, the TRX-248 system is designed as a prodrug-based transdermal platform.
In this approach, the patch delivers an inactive prodrug molecule (TRX-248) through the skin. Once absorbed into the systemic circulation, the compound is converted in the liver into active treprostinil. This prodrug strategy is intended to optimize skin permeability while enabling controlled systemic activation, potentially resulting in more stable pharmacokinetics and reduced local skin irritation compared with direct treprostinil administration.
Corsair Pharma believes this mechanism could help overcome long-standing limitations associated with prostacyclin therapy, including complex administration routes and adherence challenges. The company is also evaluating whether the platform may have broader applicability across other forms of pulmonary hypertension beyond PAH.
Positive Phase 1 Data Establishes Early Clinical Profile
The presentations at the PHA meeting will expand upon recently announced Phase 1 clinical data evaluating pharmacokinetics, safety, and tolerability of the TRX-248 Transdermal System in healthy volunteers. According to the company, the early study results demonstrated favorable systemic exposure profiles, supporting the feasibility of once-daily transdermal delivery of treprostinil via the prodrug mechanism.
Phase 1 findings indicated that the system was generally well tolerated, with manageable skin-related effects and no major safety concerns reported in the initial cohort. The pharmacokinetic data suggested consistent absorption patterns consistent with the intended design goal of maintaining steady therapeutic levels of active treprostinil over a 24-hour dosing period.
These early results are significant because prostacyclin therapies often require complex dosing regimens and can produce fluctuating drug concentrations that contribute to side effects or reduced patient adherence. A once-daily patch system that maintains stable drug exposure could represent a meaningful advancement in the management of PAH, particularly for patients requiring long-term combination therapy.
Scientific Presentations at the PHA Meeting
Corsair Pharma will present its data across three separate scientific forums during the Pulmonary Hypertension Association meeting, underscoring the importance of the TRX-248 program within the pulmonary vascular disease research community.
The first presentation will be delivered by Dr. Bobby Singh, President and Chief Operating Officer of Corsair Pharma. He will present a poster titled “Pharmacokinetics and Safety of a Novel Once-daily Treprostinil Prodrug Transdermal System in Humans.” This presentation will take place during the Unopposed Research Poster Hall Session on Thursday, June 11, from 4:00 p.m. to 5:00 p.m. The poster is expected to provide detailed insights into dosing profiles, systemic exposure data, and initial safety observations from the Phase 1 study.
In addition to the poster presentation, the TRX-248 program will be featured in the PHA Innovation Forum, a dedicated session highlighting emerging technologies and investigational therapies with the potential to transform the diagnosis and treatment of pulmonary hypertension. At this forum, R. James White, MD, PhD, Professor of Medicine, Pharmacology, and Physiology at the University of Rochester Medical Center, will present Corsair’s Phase 1 findings on June 11 from 5:00 p.m. to 6:30 p.m.
The Innovation Forum presentation is expected to contextualize the TRX-248 system within the broader therapeutic landscape, emphasizing how novel drug delivery platforms may help address unmet needs in PAH management. It will also explore how transdermal prostacyclin delivery compares with existing administration routes in terms of pharmacology, patient experience, and clinical practicality.
The third presentation will be held as part of a Corsair Product Theater session titled “Back to the Future: A Daily Treprostinil Prodrug Transdermal System Delivers Systemic Treprostinil with Modest Skin Irritation.” This session is scheduled for Friday, June 12, from 10:30 a.m. to 11:30 a.m.
The Product Theater will feature in-depth discussions led by Dr. White alongside Murali Chakinala, MD, Professor in the Division of Pulmonary and Critical Care Medicine at Washington University School of Medicine. The session will review the clinical rationale for treprostinil therapy, current challenges associated with existing delivery modalities, and early clinical findings from the TRX-248 program. The presenters are also expected to discuss the next steps in clinical development and how the technology could potentially be integrated into future treatment paradigms for PAH.
Addressing Unmet Needs in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive and life-threatening condition characterized by elevated pulmonary vascular resistance, leading to right heart failure if left untreated. Despite advances in therapy over the past two decades, PAH remains a disease with significant morbidity and mortality, and treatment complexity continues to pose challenges for patients and healthcare providers.
Prostacyclin analogs such as treprostinil play a central role in the management of moderate to severe PAH due to their potent vasodilatory and antiproliferative effects. However, traditional delivery methods often require continuous infusion pumps or frequent dosing schedules, which can negatively impact patient quality of life.
Corsair’s TRX-248 Transdermal System is being developed with the goal of simplifying prostacyclin therapy by offering a once-daily patch that delivers continuous systemic exposure. If successful in later-stage clinical trials, this approach could reduce treatment burden, improve adherence, and provide a more consistent pharmacological effect compared with current dosing strategies.
Expanding Potential Beyond PAH
While the current clinical focus of TRX-248 is pulmonary arterial hypertension, Corsair Pharma has indicated that its transdermal prodrug platform may have broader therapeutic potential. Other forms of pulmonary hypertension, which share overlapping pathophysiological mechanisms involving vascular remodeling and endothelial dysfunction, could also potentially benefit from sustained prostacyclin exposure delivered through a simplified administration method.
This broader applicability underscores the strategic interest in transdermal prodrug technology as a platform approach rather than a single-indication therapy. By enabling controlled systemic delivery of active compounds through the skin, Corsair aims to explore future applications across cardiopulmonary and vascular disease areas.
Corsair Pharma’s upcoming presentations at the 2026 Pulmonary Hypertension Association meeting mark an important milestone in the development of its TRX-248 Transdermal System. With three separate scientific forums dedicated to its Phase 1 results and clinical strategy, the company is positioning its investigational therapy as a potential next-generation prostacyclin delivery platform.
Early clinical data demonstrating favorable pharmacokinetics, tolerability, and once-daily dosing support continued development of the program. As Corsair advances toward later-stage trials, the TRX-248 system represents a promising attempt to improve both the clinical management and patient experience of pulmonary arterial hypertension through innovative drug delivery science.
About PAH and Treprostinil
Pulmonary arterial hypertension (PAH) is a serious, progressive, and ultimately fatal disease that causes shortness of breath and markedly reduces quality of life. In the U.S., approximately 45,000 patients are currently taking treatments labeled for PAH. Current therapies clearly improve function and outcomes, but there remains a tremendous unmet medical need. Importantly, many patients are unwilling or unable to utilize prostanoids, one of the most effective therapies, and Corsair believes that the TRX-248 Transdermal System could provide an important new option for them.
Treprostinil is commonly used in the treatment of PAH and exerts its pharmacological effects through vasodilation, reduced platelet aggregation, and inhibition of smooth muscle proliferation. Treprostinil is currently marketed by United Therapeutics and Liquidia in multiple formulations to alleviate symptoms, maintain or improve functional class, delay disease progression, and enhance quality of life in patients with PAH. The U.S. prostacyclin market for PAH is estimated at approximately $3.3 billion annually.
About Corsair Pharma, Inc.
Corsair Pharma is developing transformative solutions to improve the therapeutic profile of medications and provide superior treatment options for patients. The company is focused on the development of novel prodrugs of treprostinil to treat patients with Pulmonary Arterial hypertension (PAH) using a once-daily transdermal patch. The company intends to pursue a 505(b)(2) regulatory pathway, which is a streamlined process to develop new versions of approved drugs.
